ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation and CellReady, today announced that the Translational Sciences Laboratory at Gates Institute, a leading contract development and manufacturing organization (CDMO) based at the University of Colorado Anschutz Medical Campus, has been awarded a $300,000 G-Rex® Grant to develop a modular G-Rex centric CAR T-cell manufacturing platform.
“We are grateful for the generous G-Rex Grant funding, which will support the development of efficient and adaptable manufacturing approaches for our cell and gene therapy (CGT) programs,” said Dr. Veena Krishnamoorthy, Director of Translational Sciences at the Gates Institute. “The scalable and modular nature of the G-Rex platform aligns with our goals to optimize use of space, capital, and personnel while maintaining cell health and quality. We appreciate the support from Wilson Wolf and Bio-Techne in advancing our work and the broader CGT field.”
“We are pleased to award G-Rex Grant funding to the Gates Institute, a leader in bridging the academic world of discovery with clinical application to advance a diverse portfolio of innovative cell therapies for devastating cancers and rare diseases. It’s an honor to support the Gates Institute’s important contributions to the field of cell and gene therapy.” said John Wilson, CEO of Wilson Wolf and co-inventor of G-Rex.
The G-Rex Grant will support a structured Design of Experiments (DoE) to optimize key CAR-T cell manufacturing steps by systematically evaluating critical variables. The resulting data will continue to define and optimize how process conditions impact product attributes, enabling the Gates Institute to offer a broad range of manufacturing options within standardized, well-characterized design spaces for novel cell and gene therapies.
As part of the G-Rex Grant, the Gates Institute will also receive early access to CellReady’s G-CAR-TTM, a standardized CAR-T drug product manufacturing operation conceived of by CellReady, the world’s first and only G-Rex CDMO. G-CAR-TTM is ideal for high-throughput, low-cost manufacturing.
ScaleReady’s G-Rex Grant Program has authorized over $40M of products at no cost to grant recipients with the goal of advancing the state of cell and gene-modified cell therapy (CGT) development and manufacturing. Individual Grant Awards are worth up to $300,000. G-Rex Grant Recipients also gain access to exclusive support from ScaleReady’s growing consortium of G-Rex Grant Partners who bring best-in-class tools and technologies as well as unparalleled knowledge and expertise in the areas of cGMP manufacturing, quality and regulatory affairs, CGT business operations, and more.
Importantly, ScaleReady has just introduced yet another FREE program to accelerate the universal presence of highly efficient and scalable CGT manufacturing. Under this program, ScaleReady has partnered with Hanson Wade to launch an event series called LEAN Cell & GeneTM. All CGT entities are invited to attend and will learn how to systematically identify and eliminate waste, stabilize business operations, increase drug product quality and supply, and develop a LEAN approach to cell and gene therapy development and manufacturing.
Read Also: Taiko Opens Up the Next Era of Ethereum with Preconfirmations on Mainnet
